Biocon share rises as arm secures UK MHRA nod for plaque psoriasis drug

Biocon share price: Bengaluru-based pharmaceutical company Biocon shares rose as much as 1.14 per cent to hit an intraday high of ₹334.45 per share on Monday, May 26, 2025.
At 9:36 AM, Biocon share price was trading 0.73 per cent higher at ₹333.05 per share. In comparison, BSE Sensex was trading 0.79 per cent higher at 82,363.10 level.
Why did Biocon share price rise on Monday?
Biocon share price rose after the company announced that Biocon Biologics, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has been granted market authorisation in the UK for Yesintek, a biosimilar of Ustekinumab, from the Medicines and Healthcare products Regulatory Agency (MHRA), UK.
Yesintek is approved for the treatment of adults and children aged 6 years and older with moderate to severe plaque psoriasis, as well as adults with active psoriatic arthritis or moderately to severely active Crohn's disease.
Clinical trials have shown that our Ustekinumab biosimilar delivers comparable safety and efficacy to the reference product.
In Europe, the European Commission (EC) has recently granted marketing authorisation for Yesintek, enabling its commercialisation across all European Union (EU) member states and countries in the European Economic Area (EEA).
Biocon Q4 results
Biocon reported a 153 per cent year-on-year (Y-o-Y) jump in consolidated net profit to ₹344 crore for the fourth quarter of FY25, up from ₹136 crore in the same period last year.
The company's profit before tax (PBT) rose 53 per cent Y-o-Y to ₹487 crore. Total consolidated revenue for the quarter stood at ₹4,454 crore, compared to ₹3,966 crore in Q4 FY24. Ebitda increased 16 per cent to ₹1,115 crore, with the Ebitda margin maintained at 25 per cent.
The strong quarterly performance was driven by robust growth across its generics, biologics, and research services segments.
Biocon's Board has also approved a proposal to raise up to ₹4,500 crore through various instruments, including qualified institutional placement (QIP), rights issue, or other permissible routes. READ MORE
About Biocon
Biocon is among the leading global biopharmaceutical companies committed to delivering affordable, high-quality medicines and innovative therapies for chronic and complex diseases such as diabetes, cancer, and autoimmune disorders.
Operating in over 120 countries, Biocon has established a robust international presence. The company is a major player in the biosimilars segment, producing cost-effective alternatives to complex biologics like human insulin and insulin glargine.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Hindustan Times

an hour ago

• Hindustan Times

Did Barron Trump really make millions from family's cryptocurrency ventures? Here's the truth

Barron Trump, the 47th President's youngest son, may have made millions of dollars from the sale of cryptocurrency tokens connected to the family's successful foray into the digital token market, according to a new report. Barron Trump is listed as a "co-founder" of World Liberty Financial(AFP) According to Forbes, Barron, a 19-year-old student at New York University, could have received a handsome $40 million, or $25 million after taxes, through the sale of digital assets by World Liberty Financial. It is a firm owned by the Trump family that was established nine months ago after the First son convinced his father and elder brothers of the advantages of cryptocurrency. Following its launch, Trump stated in an interview last year that 'Barron knows so much about this (cryptocurrency).' 'Barron's a young guy, but he knows it — he talks about his wallet. He's got four wallets or something, and I'm saying, 'What is a wallet?'' What is World Liberty Financial? World Liberty Financial (WLF), a decentralized finance network that began operations in late 2024, is promoting its own coin $WLFI. The platform touts President Trump as its 'Chief Crypto Advocate,' and the Trump family owns 60% of the business and is eligible to receive 75% of token sales proceeds. World Liberty, which has helped Trump family to see surge in their finances, declared that it had sold $550 million worth of tokens in March. Last week, President Trump announced in an Office of Government Ethics report that he had earned $57 million from the sale of tokens. Additionally, it stated that the real estate tycoon owned 75% of his umbrella business, DT Marks Defi LLC, with the remaining 25% being owned by unidentified 'third parties.' Also Read: US warns its residents amid evacuation from Israel as Americans narrate harrowing ordeal; 'If given an option…' What is Barron Trump's position in the company? In addition to the Trump, Barron is identified as a "co-founder" of World Liberty Financial, along with the president's two other sons Donald Trump Jr. and Eric Trump. Barron reportedly possessed a 7.5% share in the Delaware-based umbrella company, according to Forbes, which offered no concrete proof for its assertions of his enormous digital profit. According to Forbes, the share would be identical to what the NYU freshman owns in the hotel owned by the Trump Organization in Washington, DC. SEC filing did not mention Barron Trump's name However, the company's only SEC filing dated October 30 of last year did not include Barron's name. Middle East diplomat Steve Witkoff and his son Zachary are mentioned as corporate partners in the enterprise. According to a Bloomberg report, Trump's net wealth has quadrupled since the beginning of his 2024 campaign and it is estimated to be above $5.4 billion.

Business Standard

an hour ago

• Business Standard

Central banks in Asia scale back currency intervention as dollar weakens

By Marcus Wong and Malavika Kaur Makol Some of emerging Asia's biggest central banks look to be dialing back their interventions in the currency market. The central banks of India and Malaysia have reduced the size of some derivatives positions they use to weaken their currencies. Taiwan has allowed its currency to surge against the dollar in recent weeks and dropped hints it would be comfortable with more if the moves were 'orderly.' South Korea's giant national pension fund has ended its five-month support of the won. A major reason for these moves is a simple change in the market landscape: The dollar has tumbled more than 7 per cent this year, easing pressure on emerging market currencies. But strategists and investors also point to the risk of a backlash from US President Donald Trump, amid rising speculation that currency policies will be on the table during a series of ongoing — and high stakes — trade negotiations. 'The threat of being labeled a currency manipulator by the US, especially during this period of tariff negotiations, will act as a deterrent to further heavy FX intervention in local markets,' said Rajeev De Mello, a Geneva-based portfolio manager at GAMA Asset Management SA. The shifting approach of Asia's central banks to defending their currencies underscores the sweeping changes in global markets since the election of Trump, whose on again-off again tariff threats have roiled asset prices and raised once unthinkable questions about the dollar's place in the global trading system. Korea confirmed last month that it had held currency talks with the US, sending the won higher amid talk that Trump wants a weaker dollar. But White House chief economist Stephen Miran has denied the idea Washington is working on secret deals to depreciate the greenback, saying the US continues to have a strong dollar policy. The greenback has plummeted against major currencies this year, suffering drops of around 10 per cent against the euro and the Swiss franc. Best bets Traders are now trying to game out which currencies have the most to gain from a period of reduced intervention. The Korean won and the Malaysian ringgit are two obvious candidates, since both countries have large trade surpluses, said Gautam Kalani, portfolio manager for BlueBay fixed income, emerging markets, at RBC Global Asset Management. Reduced intervention will speed up the appreciation of these currencies, he said. The Taiwan dollar is also being hotly tipped by strategists. Although Taiwan's central bank is still likely to use intervention to keep volatility in check, most market participants think it will allow the local currency to appreciate further even after hitting multi-year highs. That suggests room to build on what has already been a widespread rally against the dollar: Taiwan's currency has surged 11 per cent against the greenback this year, making it the region's best performer. The Korean won is up almost 8 per cent, while the Malaysian ringgit is around 5 per cent higher. The retreat from intervention isn't unanimous across Asia. Bank Indonesia pushed back against volatility on Thursday as Middle East tensions hit emerging market currencies. The Philippines' central bank has sent mixed messages, calling intervention futile but also saying it might have to do so 'more seriously' if a current slide in the peso continues. The People's Bank of China continues to keep its currency under a tight leash. But for some of emerging Asia's most interventionist central banks, the calculus appears to have shifted in favor of a less hands-on approach. The US Treasury refrained from labeling any country a currency manipulator in its latest foreign-exchange report, released in June. However, it said China, Japan, South Korea, Taiwan, Singapore and Vietnam all met two out of three of its criteria.

NDTV

2 hours ago

• NDTV

Air India To Scale Back Narrow-Body Operations Across 19 Routes Until Mid-July

New Delhi: Air India has announced a considerable but temporary five per cent reduction in its narrow-body flight operations across select domestic and short-haul international routes, citing the need to bolster operational stability. Until 15 July, the airline is temporarily suspending services on three routes and reducing frequency on 19 routes. The airline is suspending services between Bengaluru-Singapore, Pune-Singapore and Mumbai-Bagdogra - each route losing all seven weekly rotations. Key domestic arteries like Delhi, Mumbai, Bengaluru, Kolkata and Pune, and Mumbai's links to Goa, Hyderabad and other metros have also seen scaled-back schedules with reduced frequency, thereby losing between five and twelve weekly flights in each sector. This announcement comes after Air India had slashed 15 per cent of its long-haul wide-body operations across international routes following the June 12 AI 171 Dreamliner crash at Ahmedabad. Besides regulatory pressure, the airline is grappling with Middle Eastern airspace closures and night-time curfews in European and East Asian sectors. These factors have already caused 83 wide-body flight cancellations in recent days. According to the airline, the reductions are aimed at strengthening Air India's network-wide operational stability and minimising last-minute inconvenience to passengers. As the airline recalibrates its network and pursues "maximum caution", Air India seeks to assure passengers that full schedules will resume as soon as inspections clear and airspace conditions stabilise.